Some doctors are worried that early finding of a small study, which was
conducted on Alzheimer’s patients, in which they were given a popular rheumatoid arthritis drug and showed dramatic improvements, will raise premature hopes among the patients and their family.
The study involved 12 patients who were treated with anti-inflammatory drug Enbrelor etanercept, co-marketed by Amgen and Wyeth, and shortly after showed improved language-recall.
The findings were published in the journal BioMed Central BMC Neurology on Sunday.